MENU
+Compare
EXAS
Stock ticker: NASDAQ
AS OF
Mar 3, 11:40 AM (EDT)
Price
$48.51
Change
+$1.10 (+2.32%)
Capitalization
12.78B

EXAS Exact Sciences Corp Forecast, Technical & Fundamental Analysis

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally... Show more

Industry: #Biotechnology
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EXAS with price predictions
Feb 28, 2025

EXAS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on February 07, 2025

EXAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 39 cases where EXAS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXAS's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where EXAS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EXAS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EXAS turned negative on February 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for EXAS moved below the 200-day moving average on February 19, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EXAS entered a downward trend on February 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.065) is normal, around the industry mean (23.555). P/E Ratio (0.000) is within average values for comparable stocks, (82.808). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.074) is also within normal values, averaging (41.429).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EXAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

View a ticker or compare two or three
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EXAS is expected to report earnings to rise 468.83% to -34 cents per share on May 07

Exact Sciences Corp EXAS Stock Earnings Reports
Q1'25
Est.
$-0.34
Q4'24
Beat
by $0.27
Q3'24
Missed
by $0.01
Q2'24
Beat
by $0.25
Q1'24
Missed
by $0.12
The last earnings report on February 19 showed earnings per share of -5 cents, beating the estimate of -33 cents. With 183.63K shares outstanding, the current market capitalization sits at 12.78B.
A.I. Advisor
published General Information

General Information

a developer of proprietary technologies for the detection of cancer

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
5505 Endeavor Lane
Phone
+1 608 284-5700
Employees
6600
Web
https://www.exactsciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
RAMP.X0.0483440.004076
+9.21%
RAMP cryptocurrency
MTL.X0.9553350.077630
+8.84%
Metal DAO cryptocurrency
GRT.X0.1291550.010115
+8.50%
The Graph cryptocurrency
KLAY.X0.1283400.008621
+7.20%
Klaytn cryptocurrency
SC.X0.0038880.000191
+5.16%
Siacoin cryptocurrency

EXAS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.86%
QGEN - EXAS
55%
Loosely correlated
N/A
RGEN - EXAS
55%
Loosely correlated
+1.74%
FNA - EXAS
32%
Poorly correlated
+0.38%
ATEC - EXAS
29%
Poorly correlated
+3.38%
NAOV - EXAS
29%
Poorly correlated
-0.91%
More